Evidence-Based Clinical Practice Guideline for Renal Cell Carcinoma: The Japanese Urological Association 2011 update

International Journal of Urology

Volumn 19, Issue 6, 2012, Pages 496-503

  Fujioka, Tomoaki ^a   Obara, Wataru ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Clinical practice guideline; JUA 2011 update; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2;

ALGORITHM; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CLINICAL PRACTICE; EVIDENCE BASED PRACTICE; HUMAN; JAPAN; KIDNEY CARCINOMA; MEDICAL SOCIETY; METASTASIS; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; TREATMENT PLANNING; TUMOR VOLUME;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; NEPHRECTOMY; PROGNOSIS; RISK ASSESSMENT; TOR SERINE-THREONINE KINASES;

EID: 84861477307     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03031.x     Document Type: Article

References (32)

1. Fujioka T, Obara W. Evidence-based clinical practice guidelines for renal cell carcinoma (Summary - JUA 2007 Edition). Int. J. Urol. 2009; 16: 339-53.
2. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int. J. Urol. 2006; 13: 1365-70.
3. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J. Urol. 2008; 180: 515-19.
4. Iimura Y, Saito K, Fujii Y etal. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J. Urol. 2009; 181: 1004-12.
5. Naito S, Yamamoto N, Takayama T etal. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur. Urol. 2010; 57: 317-25.
6. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999; 17: 2530-40.
7. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002; 20: 289-96.
8. Thompson RH, Kaag M, Vickers A etal. Contemporary use of partial nephrectomy at a tertiary care center in the United States. J. Urol. 2009; 181: 993-7.
9. Zini L, Patard JJ, Capitanio U etal. Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma. BJU Int. 2009; 103: 894-8.
10. Zini L, Perrotte P, Capitanio U etal. Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 2009; 115: 1465-71.
11. Lucas SM, Stern JM, Adibi M, Zeltser IS, Cadeddu JA, Raj GV. Renal function outcomes in patients treated for renal masses smaller than 4cm by ablative and extirpative techniques. J. Urol. 2008; 179: 75-9.
12. Gupta A, Raman JD, Leveillee RJ etal. General anesthesia and contrast-enhanced computed tomography to optimize renal percutaneous radiofrequency ablation: multi-institutional intermediate-term results. J. Endourol. 2009; 23: 1099-105.
13. Stern JM, Gupta A, Raman JD etal. Radiofrequency ablation of small renal cortical tumours in healthy adults: renal function preservation and intermediate oncological outcome. BJU Int. 2009; 104: 786-9.
14. Davenport MS, Caoili EM, Cohan RH etal. MRI and CT characteristics of successfully ablated renal masses: imaging surveillance after radiofrequency ablation. AJR Am. J. Roentgenol. 2009; 192: 1571-8.
15. Nisbet AA, Rieder JM, Tran VQ, Williams SG, Chien GW. Decision tree for laparoscopic partial nephrectomy versus laparoscopic renal cryoablation for small renal masses. J. Endourol. 2009; 23: 431-7.
16. Berger A, Kamoi K, Gill IS, Aron M. Cryoablation for renal tumors: current status. Curr. Opin. Urol. 2009; 19: 138-42.
17. Kutikov A, Kunkle DA, Uzzo RG. Focal therapy for kidney cancer: a systematic review. Curr. Opin. Urol. 2009; 19: 148-53.
18. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 2005; Jan 25;(1): CD001425.
19. Akaza H, Tsukamoto T, Onishi T, Miki T, Kinouchi T, Naito S. A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study. Int. J. Clin. Oncol. 2006; 11: 434-40.
20. Akaza H, Kawai K, Tsukamoto T etal. Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. Jpn. J. Clin. Oncol. 2010; 40: 684-9.
21. Ito N, Eto M, Nakamura E etal. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2007; 25: 2785-91.
22. Cowey CL, Amin C, Pruthi RS etal. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 2010; 28: 1502-7.
23. Thomas AA, Rini BI, Lane BR etal. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 2009; 181: 518-23.
24. Hellenthal NJ, Underwood W, Penetrante R etal. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol. 2010; 184: 859-64.
25. Escudier B, Eisen T, Stadler WM etal. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 125-34.
26. Motzer RJ, Hutson TE, Tomczak P etal. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 115-24.
27. Hudes G, Carducci M, Tomczak P etal. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 2271-81.
28. Motzer RJ, Escudier B, Oudard S etal. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
29. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn. J. Clin. Oncol. 2007; 37: 755-62.
30. Uemura H, Shinohara N, Yuasa T etal. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn. J. Clin. Oncol. 2010; 40: 194-202.
31. Tomita Y, Shinohara N, Yuasa T etal. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 2010; 40: 1166-72.
32. Tsukamoto T, Shinohara N, Tsuchiya N etal. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn. J. Clin. Oncol. 2011; 41: 17-24.